Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group Co's quarterly accounts payable & accrued expense
declined
from Dec. 2024 ($23,255 Mil) to Jun. 2025 ($21,777 Mil) but then
increased
from Jun. 2025 ($21,777 Mil) to Dec. 2025 ($23,750 Mil).
Sinopharm Group Co's annual accounts payable & accrued expense
declined
from Dec. 2023 ($23,451 Mil) to Dec. 2024 ($23,255 Mil) but then
increased
from Dec. 2024 ($23,255 Mil) to Dec. 2025 ($23,750 Mil).
Sinopharm Group Co Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Accounts Payable & Accrued Expense Chart
Sinopharm Group Co Accounts Payable & Accrued Expense Calculation
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of $23,750 Mil mean?
Sinopharm Group Co (SHTDF) has a Accounts Payable & Accrued Expense of $23,750 Mil as of Dec. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Accounts Payable & Accrued Expense too high?
Sinopharm Group Co's current Accounts Payable & Accrued Expense is $23,750 Mil. Overall, Sinopharm Group Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Accounts Payable & Accrued Expense compare to MCK and COR?
Sinopharm Group Co's Accounts Payable & Accrued Expense of $23,750 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Medical Distribution company?
A good Accounts Payable & Accrued Expense depends on the Medical Distribution industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Accounts Payable & Accrued Expense is $23,750 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.69, compared to a current price of $2.13 — trading 20.7% below its estimated fair value. The current Accounts Payable & Accrued Expense is $23,750 Mil. Sinopharm Group Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Accounts Payable & Accrued Expense is $23,750 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 20.7% below its estimated GF Value™ of $2.69.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Accounts Payable & Accrued Expense: $23,750 Mil
GF Value™: $2.69 vs. price of $2.13 (20.7% below fair value)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
76GF Score
Get the complete analysis for SHTDF
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
